Takeda announces its intention to acquire TiGenix

TiGenix NV has announced its intention to launch a voluntary conditional takeover bid on TiGenix.

Kala pharmaceuticals announces new drug application for inveltystm (kpi-121 1%) has been accepted for review by the u.s. Food and drug administration

Minoryx Therapeutics announces the dosing of first patient in ADVANCE, a phase 2/3 clinical study of MIN-102 in patients with adrenomyeloneuropathy (AMN)

Minoryx Therapeutics, today announces the initiation of treatment of the first two patients in the ADVANCE trial, a pivotal phase 2/3 clinical trial of MIN-102 for the treatment of adrenomyeloneuropathy (AMN).

Aura Biosciences Completes $30 Million Series C Financing

The company plans to use proceeds from this round of financing to expand infrastructure supporting ongoing clinical development.

Sanifit Announces Last Patient Last Visit completed in Clinical Trial of SNF472 in Patients with Calciphylaxis

Laboratoris Sanifit S.L., announced today that the Last Patient's Last Visit (LPLV) occurred in the Phase II study of SNF472, its lead candidate for the treatment of the orphan disease calciphylaxis (calcific uraemic arteriolopathy, CUA) for which there is currently no approved agent.

Sanifit appoints Alexander M. Gold, M.D., F.A.C.C. as Chief Medical Officer and President of its US subsidiary

Laboratoris Sanifit S.L., today announces the appointment of Alexander M. Gold, M.D., F.A.C.C. as Chief Medical Officer and President of its US subsidiary Sanifit Inc.

Aura Biosciences Strengthens Leadership Team with Addition of Cadmus Rich, M.D., as Chief Medical Officer

Aura Biosciences, today announced that Cadmus Rich, M.D., has joined the company’s leadership team as Chief Medical Officer.

MedLumics Appoints Medtech Industry Veterans James Greene as Chief Executive Officer and Giovanni Leo as Member of the Board of Directors

MedLumics, announced today it has appointed James Greene as Chief Executive Officer and named Giovanni Leo to the board of directors.

Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs

The funding round was led by a global strategic investor with participation from venture capital fund Ysios Capital and a number of large private investors.

CorWave Receives 2017 Deloitte ‘Technology Fast 50 Biotech of the Future’ Award of the Parisian Region

CorWave, announced today that it received the 'Deloitte In Extenso Technology Fast 50 Biotech of the Future' award for the Parisian Region.